“…9,10 This characteristic allows FTM to cross the blood-brain barrier (BBB), as shown by experimental studies in animals. 11,12 In addition, as FTM does not significantly alter glutathione reductase activity, a more favorable pulmonary toxicity profile for this agent can be predicted compared with BCNU. 13 In fact, several clinical trials have confirmed that FTM, unlike other nitrosoureas, shows no significant pulmonary toxicity.…”